A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT04732221
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 168 participants
- Sponsor
- Registry
-
NCT04732221 -
2022-500877-15-00 -
U1111-1278-4977 -
2020-001108-40
-
- Other papers using this trial's data
- MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russia, Sweden, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04732221. Randomized; triple masking; primary purpose treatment. Start 2021-05-19 (actual); primary completion 2024-01-04 (actual). Results posted on 2025-02-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
- Condition
- Pulmonary Arterial Hypertension
- Condition
- Hypertension, Pulmonary
- Intervention (Drug)
- Frespaciguat
- Intervention (Drug)
- Placebo to Frespaciguat
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct04732221- Content hash
a8c0578e5d0a9d02f58c479aa9787ad5c963432e4a6f53e26c5ef1dc0d539406